OR WAIT null SECS
Click here to read the articles and download the PDF
How drugmakers can better harness real-world evidence to drive their clinical and commercial objectives, while also providing greater clarity for healthcare providers and improved access to therapy for the patients they serve.
While new forms of pharmacy continue to surface beyond brick-and-mortar retail, a look at what is driving this shift in perspective—and "pharmacies of the future"—is warranted.
Methods that pharma companies can use to make the hub more personalized and experiential.
December 06, 2023
A study explores how supply and demand impact the value of medication.
Novartis anticipates Fabhalta to be available in the United States in December for the treatment of paroxysmal nocturnal hemoglobinuria.
How to provide effective brand engagement in this rocky yet emerging landscape.
Matt Wolf, president of biopharma services, Cencora, discusses the importance of partnership in helping to combat prescription drug abandonment and non-adherence.
December 05, 2023
What stands between pharma and other industries when it comes to remaining vigilant?
Eli Lilly and Company's obesity drug Zepbound (tirzepatide) has a list price of $1,059.87, which is approximately 20% less than the 2.4 mg semaglutide injection indicated for weight loss.
Johnson & Johnson’s TAR-200 has a novel targeted releasing system that allows for a controlled release of gemcitabine in patients with Bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer.
Opdivo (nivolumab) plus cisplatin-based chemotherapy shows improved survival benefits in the first-line treatment of adults with unresectable or metastatic urothelial carcinoma.
December 04, 2023
Critical factors need to be addressed for pharma stakeholders to realize the full potential of generative artificial intelligence.